Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

MRI-Guided radiation trial aims to sharper target pelvic tumors

NCT ID NCT07083648

Knowledge-focused Sponsor: University of Zurich Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a new method of radiation therapy, which uses an MRI scan to plan treatment and a CT scan to deliver it, is feasible for treating pelvic lymph node metastases. Twenty adults with confirmed cancer spread to pelvic lymph nodes will receive stereotactic body radiation therapy (SBRT) using this approach. The main goal is to see if the MRI-adapted plan can be successfully delivered in 90% of cases.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 20 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2025

Expected to finish

Jan 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Intra-pelvic and para-aortic lymph node metastases from a histologically confirmed malignancy; * Indication for SBRT based on a multidisciplinary tumor board recommendation and / or clinical practice guideline; * Intra-pelvic and para-aortic lymph node metastases confirmed by imaging and amenable for SBRT Exclusion Criteria: * Large body size that would not fit the MRI-simulator bore; * Contraindications for MRI including but not limited to * electronic devices such as pacemakers, defibrillators, deep brain stimulators, cochlear implants that are labeled as MR unsafe. Electronic devices labeled as MR safe or MR conditional are not a contraindication; * metallic foreign body in the eye or aneurysm clips in the brain; * severe claustrophobia; * hip prosthesis that are labeled as MR unsafe; * More than 5 pelvic lymph node metastasis * Previous radiation therapy directly overlapping with SBRT in this study and leading to exceeding tolerance of OARs; * History of Crohn's disease, ulcerative colitis

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pelvic and para-aortic lymph node metastases are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

metastatic malignant neoplasm in the lymph nodes

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pelvic and para-aortic lymph node metastases

Contacts and locations

Locations

  • Zurich University Hospital, Department of Radiation Oncology

    Zurich, Canton of Zurich, 8091, Switzerland